Herkinorin
Herkinorin is a semi-synthetic opioid analgesic that has been derived from the natural product Salvinorin A. It was discovered in 2005 by a team at Purdue University led by Richard B. Rothman and Kenner C. Rice. Herkinorin is the first compound found to be a full agonist for the peripheral μ-opioid receptor that does not significantly recruit β-arrestin-2 after binding to and activating the receptor.
Chemistry[edit]
Herkinorin is a semi-synthetic compound, which means it is not found in nature but is instead synthesized from natural products. It is derived from Salvinorin A, a psychoactive compound found in the plant Salvia divinorum. The chemical structure of Herkinorin is similar to that of other opioids, with a basic nitrogen atom and a phenolic hydroxyl group.
Pharmacology[edit]
Herkinorin acts as a full agonist at the μ-opioid receptor, but unlike most other μ-opioid receptor agonists, it does not significantly recruit β-arrestin-2. This is significant because the recruitment of β-arrestin-2 is associated with the development of opioid tolerance and dependence. Therefore, Herkinorin may have potential as a new type of opioid analgesic that is less likely to produce these side effects.
Research[edit]
Research on Herkinorin is still in the early stages, but initial studies suggest that it may have potential as a new type of opioid analgesic. Further research is needed to fully understand the pharmacology of Herkinorin and to determine its efficacy and safety in humans.
See also[edit]
References[edit]
-
Herkinorin
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
